Fimasartan
PreclinicalSmall molecule
Boryung Pharmaceutical Co., LtdFimasartan is a small molecule that works as a Type-1 Angiotensin II Receptor Antagonist.[2] It is being investigated across 3 indications, with its most advanced program in Preclinical.[1]
Fimasartan is one of 80 small molecule programs targeting Cardiovascular Disease. It is currently in Preclinical.
3
Indications
45
Total Trials
0
Active Trials
79
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
146 competitors in Cardiovascular Disease
#DrugCompanyPhaseTrials
1Cardene
Sun Pharmaceutical Industries, Inc.Approved
Primacor
SanofiApproved
Geodon
PfizerApproved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Giapreza
LLa Jolla Pharmaceutical Company
Approved
Camzyos
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Midamor
PPadagis LLC
Approved
Colcrys
Jazz PharmaceuticalsPhase 3
Pelacarsen
NovartisPhase 3
Cagrilintide
Novo NordiskPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Essential Hypertension10 trials
Show 7 more trials
Clinical Trial4 trials
Atorvastatin3 trials
Interaction3 trials
Hypertension3 trials
20 more indications
Tics2 trials
Blood Pressure2 trials
Comparison of Blood Pressure Lowering Effect Between Fimasartan and Losartan
Unknown status·—·Phase 4·NCT02958631·40 enrolled
Elderly1 trial
Diastolic Heart Failure1 trial
A Trial of Fimasartan for Early Diastolic Heart Failure
Completed·—·Phase 4·NCT01691118·60 enrolled
Efficacy and Safety1 trial
Statin1 trial
Ischemic stroke1 trial
Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol
Unknown status·—·Phase 4·NCT02403349·105 enrolled
Type 2 Diabetes1 trial
Coronary Disease1 trial
Hepatic Impairment1 trial
Renal Impairment1 trial
Left Ventricular Hypertrophy1 trial
Oral1 trial
Aortic Stenosis1 trial
Efficacy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fimasartan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details